Efficacy and Safety of BMSCs (CG-BM1) for ACLF Patients
Status:
RECRUITING
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection (hereinafter referred to as CG-BM1) can treat acute-on-chronic liver failure (ACLF) patients. Main purposes of this clinical trial are:
* To evaluate the safety and tolerability of CG-BM1 for the treatment of adult patients with ACLF.
* To observe the preliminary effectiveness of CG-BM1 in treating adult ACLF patients, and to provide a basis for subsequent clinical trial protocol design.